Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Veracyte (VCYT)

Veracyte raises 2026 revenue and EBITDA margin guidance after 21% Q1 revenue growth

Positive Impact 4 of 5 guidance Written later

Veracyte reported first-quarter 2026 total revenue of $139.1 million, up 21% from a year earlier, and GAAP net income of $28.7 million, compared with $7.0 million in the first quarter of 2025. The company raised its 2026 total revenue guidance to $582 million to $592 million and its adjusted EBITDA margin guidance to greater than 26%, which shareholders may view as a sign that growth is running ahead of earlier expectations.

Key points

  • Total revenue was $139.1 million, up 21% from $114.5 million; testing revenue was $135.1 million, up 26%.
  • GAAP net income was $28.7 million, or $0.35 per diluted share, versus $7.0 million, or $0.09 per diluted share, a year earlier.
  • 2026 total revenue guidance was raised to $582 million to $592 million from $570 million to $582 million.
  • Adjusted EBITDA margin guidance was raised to greater than 26% from approximately 25%.

The filing

CompanyVeracyte (VCYT)
Form8-K, current report
Filed with the SECMay 5, 2026, 4:08 PM ET
Accession number0001384101-26-000029

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.